Novavax execs could get big payday even if vaccine fails – ZAWYA

Novavax execs could get big payday even if vaccine fails – ZAWYA

novavax execs could get big payday even if vaccine fails novavax said the stock options were awarded to retain its top talent and recognize their intense effort    one of the leading u.s. firms developing a coronavirus vaccine, novavax inc, has awarded executives stock options that could pay out tens of millions of dollars even if its efforts fail.novavax ceo stanley erck and three other executives would earn the options, worth $101 million at tuesday's closing stock price, if the company's vaccine candidate enters a mid-stage clinical trial - regardless of its eventual success, according to a company filing. the incentive plan, which has not been previously reported, allows the executives to start exercising the options a year after novavax starts the so-called phase 2 trial, as it expects to do soon.starting the phase 2 trial is no guarantee the vaccine candidate will make it to market. novavax would have to successfully complete more extensive phase 3 trials and win approval from the u.s. food and drug administration.novavax ceo stanley erck and three other executives would earn the options, worth $101 million at tuesday's closing stock price, if the company's vaccine candidate enters a mid-stage clinical trial - regardless of